The last two decades have witnessed major breakthroughs in the development of targeted
therapy for patients with metastatic colorectal cancer (mCRC), an achievement which stems …

Simple Summary Molecularly targeted therapies have greatly contributed to the
development of colorectal cancer treatments. Genomic profiling to identify gene alterations is …

Background Anti-EGFR antibodies plus doublet chemotherapy is the standard of care in
RAS/BRAF wild-type metastatic colorectal cancer (mCRC). No phase-3 level of evidence is …

Anti-EGFR targeting is one of the key strategies in the treatment of metastatic colorectal
cancer (mCRC). For almost two decades oncologists have struggled to implement EGFR …

在全球范围内结直肠癌已经是最常见的癌症之一. 近些年来, 结直肠癌持续上升的发病率给社会
经济带来了巨大压力. 尽管治疗手段在不断地进步, 但是结直肠癌的死亡率仍居高不下 …

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of
cancer death worldwide. Clinical research results have provided more treatment …

With improvements across the colorectal cancer care continuum, from screening and earlier
detection to better systemic options, patients are living longer with the disease. Given these …

Over the course of nearly six decades since the inception of initial trials involving 5-FU in the
treatment of mCRC (metastatic colorectal cancer), our progressive comprehension of the …

Background Triplet chemotherapy plus cetuximab showed promising results in phase II trials
in unsystematically selected RAS population. We evaluated FOLFIRINOX+ cetuximab …

Background Metastatic colorectal cancer is one of the most common causes of cancer death
worldwide. RAS and BRAF mutational analyses are strongly recommended before …